Related Experiment Video
Updated: Jun 26, 2026
Application of Retinoic Acid to Obtain Osteocytes Cultures from Primary Mouse Osteoblasts
Published on: May 14, 2014
Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow
Ujjal K Singha1, Yu Jiang, Shibing Yu
1Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15240, USA.
Abstract:
While the roles of the mammalian target of rapamycin (mTOR) signaling in regulation of cell growth, proliferation, and survival have been well documented in various cell types, its actions in osteoblasts are poorly understood. In this study, we determined the effects of rapamycin, a specific inhibitor of mTOR, on osteoblast proliferation and differentiation using MC3T3-E1 preosteoblastic cells (MC-4) and primary mouse bone marrow stromal cells (BMSCs). Rapamycin significantly inhibited proliferation in both MC-4 cells and BMSCs at a concentration as low as 0.1 nM. Western blot analysis shows that rapamycin treatment markedly reduced levels of cyclin A and D1 protein in both cell types. In differentiating osteoblasts, rapamycin dramatically reduced osteoblast-specific osteocalcin (Ocn), bone sialoprotein (Bsp), and osterix (Osx) mRNA expression, ALP activity, and mineralization capacity. However, the drug treatment had no effect on osteoblast differentiation parameters when the cells were completely differentiated. Importantly, rapamycin markedly reduced levels of Runx2 protein in both proliferating and differentiating but not differentiated osteoblasts. Finally, overexpression of S6K in COS-7 cells significantly increased levels of Runx2 protein and Runx2 activity. Taken together, our studies demonstrate that mTOR signaling affects osteoblast functions by targeting osteoblast proliferation and the early stage of osteoblast differentiation.
Insights
The mammalian target of rapamycin (mTOR) pathway regulates osteoblast proliferation and early differentiation. Inhibiting mTOR with rapamycin reduces osteoblast growth and key differentiation markers, impacting bone formation.
Area of Science:
- Biochemistry
- Cell Biology
- Orthopedics
Background:
- Mammalian target of rapamycin (mTOR) signaling is crucial for cell growth, proliferation, and survival.
- The specific role of mTOR signaling in osteoblasts remains largely uncharacterized.
Purpose of the Study:
- To investigate the effects of mTOR inhibition on osteoblast proliferation and differentiation.
- To elucidate the molecular mechanisms underlying mTOR's influence on osteoblast function.
Main Methods:
- Utilized MC3T3-E1 preosteoblastic cells and primary mouse bone marrow stromal cells (BMSCs).
- Administered rapamycin, a specific mTOR inhibitor, at varying concentrations.
- Performed Western blot analysis for protein levels (cyclin A, D1, Runx2) and assessed osteoblast-specific gene expression (Ocn, Bsp, Osx), alkaline phosphatase (ALP) activity, and mineralization.
Main Results:
- Rapamycin significantly inhibited proliferation in both MC-4 cells and BMSCs at 0.1 nM.
- Rapamycin reduced cyclin A and D1 protein levels and suppressed osteocalcin, bone sialoprotein, and osterix mRNA expression, ALP activity, and mineralization in differentiating osteoblasts.
- Rapamycin decreased Runx2 protein levels in proliferating and differentiating osteoblasts but not in fully differentiated cells.
- Overexpression of S6K increased Runx2 protein levels and activity.
Conclusions:
- mTOR signaling plays a significant role in regulating osteoblast proliferation.
- mTOR signaling targets the early stages of osteoblast differentiation, influencing key transcription factors like Runx2.
- These findings highlight mTOR as a potential therapeutic target for modulating bone formation.
More Related Videos
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:31Osteoclasts in Bone Remodeling